|
|
|
|
||
Markets weak/Pharma firm; $0.83, 107k; 45k Germany; 57k US; BoD Six Pack!Mr. House Positions: I agree with you that it's a good sign that the BoD is settling in! Keep in mind, what shareholders have witnessed is a kind of Revolution with a Change of "Government". Summary: Markets weak/Pharma firm; $0.83, 107k; 45k Germany; 57k US; BoD Six Pack! Today's excellent news (short form below) confirms that the New Kids on the BoD Block have verve and competence, a Great Thing for All Shareholders! @JWCEO Sernova's BoD The Dirty Six Pack :) The newly constituted Board has appointed Mr. Brett Whalen as its new Chair... the Company intends, as an act of good faith, and in the interest of fully aligning Sernova shareholders with Management and the Board, to reimburse the Concerned Shareholders Group for their reasonable AGM related expenses.... Lastly, Sernova Directors Ms. Deborah Brown and Dr. Mohammad Azab have retired from the Company’s Board, effective May 30th. https://money.tmx.com/en/quote/SVA/news/4794550712881990/Sernova_Announces_Executive_Alignment_and_Appoints_New_Board_Chair There has been considerable action on the BB's, which I won't repost here save for some links. This one is a heads up to Dr. Toleikis to do "Something". Time is running out. The pharmaceutical world is diligently progressing matters such that Sernova runs the risk of losing market share, or competing at a lower price point because of Being Late on everything! @JWCEO Pfizer sends a shot across Sernova's bow re: Hemophilia A and B with a once a week injection! Two excerpts: 1) The drug, marstacimab, is being evaluated in hemophilia A as well as the less common hemophilia B. Standard of care for both forms of hemophilia includes clotting factor treatments, infusions of the clotting proteins that patients lack. But these therapies don’t last long in the body, so they must be administered every two-to-three days. Pfizer’s once-weekly injectable drug is a non-factor therapy. 2) Hemophilia A patients already have a non-factor drug option — Hemlibra. That blockbuster Roche drug is an antibody designed to mimic the function of a clotting protein called factor VIII. Its FDA approval covers the prevention of bleeding episodes. Marstacimab is also an antibody, but the Pfizer drug works in a different way. It’s designed to block tissue factor pathway inhibitor (TFPI), an anticoagulant protein in the body that inhibits the start of the blood clotting process. According to Pfizer, by targeting the Kunitz-2 domain of this protein, marstacimab may help reestablish the balance between bleeding and blood clot formation. https://medcitynews.com/2023/05/pfizer-hemophilia-antibody-drug-bleeding-clinical-trial/ Dr. Toleikis must show us that he can on the Business Side whereas, so far, he's shown us he can't. Your call Dr. Toleikis, can you, or can't you? That is the question!! jwall Sent: 5/31/2023 4:51:16 PM Subject: A good sign... the BOD is settling in! Today: Week so far: |
return to message board, top of board |